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Abstract
This commentary expands on two of the key themes briefly raised in the paper involving analysis of the evidence 
about key contextual influences on decisions of value. The first theme focuses on the need to explore in more 
detail what is called backstage decision-making looking at how actual decisions are made drawing on evidence 
from ethnographies about decision-making. These studies point to less of an emphasis on instrumental and 
calculative forms of decision-making with more of an emphasis on more pragmatic rationality. The second 
related theme picks up on the issue of sources of information as a contextual influence particularly highlighting 
the salience of uncertainty or information deficits. It is argued that there are a range of different types of 
uncertainties, not only associated with information deficits, which are found particularly in allocative types of 
decisions of value. This means that the decision-making process although attempting to be linear and rational, 
tends to be characterised by a form of navigation where the decision-makers navigate their way through the 
uncertainties inherent and overtly manifested in the decision-making process.
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The importance of understanding the contextual influences on decision-making about cost and quality related questions in the organisation and provision of 
healthcare is well recognised.1 However, this paper2 goes one 
stage further by carrying out a structured evidence review 
and narrative synthesis trying to identify the evidence from 
the international available literature about the key contextual 
influences. A distinction is made between allocative and 
technical types of decisions of value with the bulk of evidence 
being found in relation to the former rather than the latter 
type of decision-making. The analysis, drawing on the 
framework provided by Pettigrew,3 identifies a number of 
inner and outer contextual influences on what the authors call 
‘decisions of value.’ In terms of the contextual influences these 
are categorised in terms of sources of information; interests; 
organisational characteristics, governance and leadership, 
geography, economics and relationship to government. The 
focus is at the meso level, as opposed to the micro- and macro-
levels, and on more formal aspects of decision-making.
The paper provides a useful presentation of the state of 
the evidence about contextual influences but tends to pay 
limited attention to what might be called backstage4 as 
opposed to front stage decision-making. This is alluded to 
in the paper but it is central to understanding how decisions 
get made. For example, in the area of priority setting these 
decision-making processes have been described, at least 
some time ago, as ‘muddling through elegantly’ where there 
is more evidence of negotiation rather than rationality or 
instrumentality in decision-making.5 This type of decision-
making process is messy and non-linear, and in spite of 
apparent significant changes in the quality of evidence 
available and the sophistication of techniques used to 
analyse these data, has still been found at different levels of 
decision-making in the public funded national health service 
in England. For example, research focusing at the national 
level involving the ‘fourth’ stage of medicine regulation and 
which has explored decision-making by the National Institute 
for Health and Care Excellence (NICE) about the appraisal 
of expensive medicines has identified the difference between 
front stage and backstage decision-making. The discourse 
associated with front stage decision-making emphasises 
the dominant influence of the technical criteria of cost-
effectiveness although in some cases social values tended 
to receive some explicit recognition in the decision-making 
such as in the treatment for younger children. The attempt to 
explicitly incorporate social and ethical values was shaped by 
an approach described as ‘accountability for reasonableness’ 
which emphasised the conditions of transparency, relevance, 
and revisabilty.6 Evidence about the implementation of 
policies in some countries based on this ‘accountability 
for reasonableness’ approach is available.7 However, this 
evidence tends to focus on decision-making at the formal 
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level and the research evidence from ethnographic studies 
involving interviews, documentary analysis and observation 
points suggests that while the discourse particularly on 
cost-effectiveness did generally frame the approach taken a 
less than rational or calculative approach in the backstage 
decision-making was prevalent. This research identifies the 
implicit social influences about how decisions are made and 
suggest that the decision-making process is characterised 
by a form of navigation, (rather than ‘muddling through’) 
where the decision-makers navigate their way through 
the uncertainties inherent in what is formally described as 
evidence-based decision-making process.8 The paper suggests 
that ‘cost effectiveness analysis which has been applied with 
some success to allocative decision-making at a macro level’ (p. 
11).2 The evidence from ethnographic studies9 suggest that 
this account may only present a partial picture of the nature 
of the decision-making process and what shapes it. 
Similarly at the more local level decisions about the 
commissioning might also be characterised as practical 
rationality and involve intuition and experiential knowledge9 
and a ‘case and judgement based’ approach.10 In both these 
national and local level contexts the use of practical rationality 
is evident but appeared to complement the dominant 
instrumental discourse, although in the local context 
emphasis in the discussion on ethical issues in relation to the 
allocation of resources was not only more overt but related 
more directly to individual circumstances. 
A related issue is the question of sources of information which 
is identified as one of the key contextual elements. The paper 
identifies the importance of the absence of information ‘high 
levels of uncertainty in the face of information deficits have 
been shown to reduce adherence to an instrumental decision-
making model and to open up determinations to greater levels 
of judgement and intuition’ (p. 9).2 Thus, there is recognition 
of the salience of uncertainty in the context of these decision-
making and the implications for rational decision-making. 
However, studies have shown that in allocative decision-
making there are different types of uncertainties not only 
associated with information deficits and these will need to be 
recognised and be managed if a decision is to be made. Three 
different types of uncertainty have been identified which are 
interrelated in the decision-making process11 which were 
epistemic (referring to the ability of biomedical methods used 
by the pharmaceutical industry to produce knowledge about 
treatments), procedural (particularly relating to the sheer 
volume of evidence considered), and interpersonal (which 
refers to the competency and motives of those providing 
evidence such as the representatives from the pharmaceutical 
industry and clinical experts). There was also uncertainty 
and ambiguity associated with the level of technicality and 
complexity of the information provided.8 Agencies such as 
NICE recognise, attempt to address and try to resolve some 
of these epistemological uncertainties particularly through 
quantitative techniques.12 However, the evidence8 also 
suggested that navigation of these layers of uncertainty was 
(partially) managed through practical rationality and various 
forms of trust at different levels. Trust was one of a number 
of means used to bridge uncertainty. Both individual decision 
as rules of thumb and collective strategies were evident in the 
management of uncertainty in the decision-making process. 
Thus, though seemingly an objective techno-scientific 
evaluation, social forces necessarily emerge in the development 
and subsequent management of uncertainty.8
There is some disagreement over how these uncertainties 
should be tackled although there is consensus that they 
should be recognised and acknowledged rather than ignored 
and being bracketed off. However, while one approach tends 
to want to minimise them as they are seen as a problem13 
whereas the other see uncertainty more positively as a way 
of making rationing decisions more transparent, accountable 
and democratic.14 
The review paper2 identifies the significance of external and 
internal interests but says little about the key role of commercial 
interests in influencing decision-making even though some 
appear to have been identified in the papers reviewed. It 
might be argued that the profit motive which might be the 
primary driver of these commercial interest groups which 
could be at odds with the public interest and the professional 
values of those providing the healthcare. This would include 
the influence of corporate private companies who finance and 
provide healthcare and of the multi-national pharmaceutical 
industry. For example, the study8 previously described also 
illustrated the potential risks of regulatory capture15,16 of NICE 
in England by the pharmaceutical industry although there are 
both formal and informal mechanisms to attempt to manage 
and resist their influence. In this case the pharmaceutical 
industry might be characterised as both an external and 
internal contextual influence given that it contributes to the 
process by providing and controlling access to evidence about 
cost effectiveness but is not directly involved in the decision-
making. 
More generally, the organising framework developed by 
Pettigrew3 based on an organisation outside of health system 
in the industrial sector is used to analyse the difference 
between external and internal contextual influences. It 
must be emphasised that this framework relates primarily 
to health systems in high income countries and tends to 
focus on, although not explicitly stated, organisational and 
political influences rather than cultural context.17,18 This is a 
useful descriptive schema for categorising and classification 
but as the authors suggest it is a framework mainly used 
for analysing change processes rather than explaining the 
relative importance of different layers of contextual influence. 
Certainly, it is difficult to assess the explanatory power of 
the framework given that it was not specifically designed for 
this particular purpose. One area that needs to be discussed 
in more depth is the dynamic nature of the decision-making 
process and the interrelationship between the different 
layers of the influence. These may be at the macro, meso and 
micro levels and the question is which are the most powerful 
contextual influences? Alternative theoretical approaches 
such as the structural interest approach of Alford19 might 
shed more light on this. The paper proposes2 that the 
evidence suggests that internal influences appear to be more 
powerful although much depends upon the latitude available 
to local actors in their decision-making. Local managers and 
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clinicians, at least in the National Health Service (NHS) in 
England, tend to have some degree of relative autonomy and 
discretion but it has been suggested that the interplay between 
corporate monopolisers and professional rationalisers19,20 
might shape the decision-making process in many healthcare 
organisational settings which in turn could limit in particular 
the influence of bottom-up pressures.
The influence of bottom up pressures is raised in the paper2 
through discussion of the role of the patients in decision-
making and the importance of hearing the patient voice. This 
should certainly help democratise health services and mitigate 
against the dominance of managerial and professional interests 
as well enhance patient centred care and the coproduction of 
knowledge.14 However, it has proved difficult sometimes to 
square specific patients interests with more general decisions 
about the allocation of resources and disinvestment decisions 
ie, what benefits the specific patient group may not be 
beneficial for the population as a whole.21,22
Finally, from a methodological point of view the studies 
discussed here have tended to adopt ethnographic designs 
although those reviewed in the paper seem to be short on 
the use of this type of methodology involving observation 
to directly understand how and why decisions are made in 
everyday contexts. The lack of such studies creates considerable 
limitations for gaining insights into understanding the nature 
of decision-making and its evidence base.
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